dc.contributor.author | Ramos Pinheiro, R | |
dc.contributor.author | Diamantino, F | |
dc.contributor.author | Cabete, J | |
dc.contributor.author | Brasileiro, A | |
dc.contributor.author | Baptista, J | |
dc.contributor.author | Paiva Lopes, MJ | |
dc.date.accessioned | 2023-10-06T14:19:20Z | |
dc.date.available | 2023-10-06T14:19:20Z | |
dc.date.issued | 2017-12 | |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Int J Dermatol . 2017 Dec;56(12):1461-1464. | pt_PT |
dc.identifier.doi | 10.1111/ijd.13752 | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/4709 | |
dc.language.iso | eng | pt_PT |
dc.publisher | Wiley | pt_PT |
dc.subject | HSAC DER | pt_PT |
dc.subject | Adolescent | pt_PT |
dc.subject | Child | pt_PT |
dc.subject | Adalimumab / therapeutic use | pt_PT |
dc.subject | Biological Products / adverse effects | pt_PT |
dc.subject | Biological Products / therapeutic use* | pt_PT |
dc.subject | Humans | pt_PT |
dc.subject | Female | pt_PT |
dc.subject | Male | pt_PT |
dc.subject | Child, Preschool | pt_PT |
dc.subject | Dermatologic Agents / adverse effects | pt_PT |
dc.subject | Dermatologic Agents / therapeutic use* | pt_PT |
dc.subject | Drug Substitution / trends* | pt_PT |
dc.subject | Etanercept / therapeutic use | pt_PT |
dc.subject | Infliximab / therapeutic use | pt_PT |
dc.subject | Psoriasis / drug therapy* | pt_PT |
dc.subject | Retrospective Studies | pt_PT |
dc.subject | Severity of Illness Index | pt_PT |
dc.subject | Ustekinumab / therapeutic use | pt_PT |
dc.title | Switching Biologics in Severe Pediatric Psoriasis: a Retrospective Analysis | pt_PT |
dc.type | other | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 1464 | pt_PT |
oaire.citation.issue | 12 | pt_PT |
oaire.citation.startPage | 1461 | pt_PT |
oaire.citation.title | International Journal of Dermatology | pt_PT |
oaire.citation.volume | 56 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | other | pt_PT |